Systemic contribution of inflammatory mediators to the severity of diabetic and uveitic macular edema.
Cytokine
Diabetic macular edema
Interleukin-6
Interleukin-8
Macular volume
Uveitic macular edema
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
26
07
2020
accepted:
02
03
2021
revised:
24
01
2021
pubmed:
13
3
2021
medline:
25
8
2021
entrez:
12
3
2021
Statut:
ppublish
Résumé
To assess whether serum cytokine and growth factor levels are associated with diabetic macular edema (DME) and uveitic macular edema (UME) objective severity. Cross-sectional observational study of 81 patients (1 eye/patient) with DME (n=48) and UME (n=33). Macular edema (ME) was defined upon central macular thickness (CMT) ≥ 300 μm on spectral domain optical coherence tomography (OCT). Serum samples were obtained from peripheral blood and IL-1β, IL-6, IL-8, IL-10, MCP-1, TNF-α, and VEGF levels were determined by Luminex analysis. Main outcome measure was the correlation between mediators' levels and CMT and macular volume (MV) on OCT for ME cases. In DME, IL-6 levels were found to significantly correlate with MV (r=0.324; p=0.028) whereas in UME, IL-8 was significantly associated with both CMT (r=0.401; p=0.021) and MV (r=0.391; p=0.024). IL-8 independently correlated with CMT (ß=177.2; p=0.033) and MV (ß=3.17; p=0.008) in UME multivariate model. Peripheral blood IL-6 and IL-8 levels could play a role in the severity of DME and UME, respectively. IL-8 even seems to be independently associated with CMT and MV in UME cases. Such systemic implications could enforce DME and UME personalized diagnostic and therapeutic approaches.
Identifiants
pubmed: 33710470
doi: 10.1007/s00417-021-05149-5
pii: 10.1007/s00417-021-05149-5
doi:
Substances chimiques
Inflammation Mediators
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2695-2705Subventions
Organisme : Instituto de Salud Carlos III
ID : PI17/00316
Organisme : Departament d'Innovació, Universitats i Empresa, Generalitat de Catalunya
ID : 2017 SGR 0701
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Klein R, Klein BE, Moss SE (1984) Visual impairment in diabetes. Ophthalmology 91(1):1–9
pubmed: 6709312
doi: 10.1016/S0161-6420(84)34337-8
Klein R, Klein BE, Moss SE et al (1995) The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long-term incidence of macular edema. Ophthalmology 102(1):7–16
pubmed: 7831044
doi: 10.1016/S0161-6420(95)31052-4
Yau JW, Rogers SL, Kawasaki R et al (2012) Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564
pubmed: 22301125
pmcid: 3322721
doi: 10.2337/dc11-1909
Lardenoye CW, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113(8):1446–1449
pubmed: 16877081
doi: 10.1016/j.ophtha.2006.03.027
Malinowski SM, Pulido JS, Folk JC (1993) Long-term visual outcome and complications associated with pars planitis. Ophthalmology 100(6):818–824
pubmed: 8510893
doi: 10.1016/S0161-6420(93)31567-8
Prieto-del-Cura M, González-Guijarro J (2009) Complications of uveitis: prevalence and risk factors in a series of 398 cases. Arch Soc Esp Oftalmol 84(10):523–528
pubmed: 19902397
doi: 10.4321/S0365-66912009001000007
Massa H, Pipis SY, Adewoyin T et al (2019) Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol 10(13):1761–1777
doi: 10.2147/OPTH.S180580
Das A, McGuire PG, Rangasamy S (2015) Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology 122(7):1375–1394
pubmed: 25935789
doi: 10.1016/j.ophtha.2015.03.024
Daruich A, Matet A, Moulin A et al (2018) Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res 63:20–68
pubmed: 29126927
doi: 10.1016/j.preteyeres.2017.10.006
Vujosevic S, Simó R (2017) Local and systemic inflammatory biomarkers of diabetic retinopathy: an integrative approach. Invest Ophthalmol Vis Sci 58:BIO68–BIO75. https://doi.org/10.1167/iovs.17-21769
doi: 10.1167/iovs.17-21769
pubmed: 28510630
Dong N, Xu B, Chu L et al (2015) Study of 27 aqueous humor cytokines in type 2 diabetic patients with or without macular edema. PLoS One 10(4):e0125329
pubmed: 25923230
pmcid: 4414516
doi: 10.1371/journal.pone.0125329
Jonas JB, Jonas RA, Neumaier M et al (2012) Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina 32:2150–2157
pubmed: 22617833
doi: 10.1097/IAE.0b013e3182576d07
Valentincic NV, de Groot-Mijnes JD, Kraut A et al (2011) Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis 17:2003–2010
pubmed: 21850175
pmcid: 3154134
Fine HF, Baffi J, Reed GF et al (2001) Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 132(5):794–796
pubmed: 11704050
doi: 10.1016/S0002-9394(01)01103-5
Hillier RJ, Ojaimi E, Wong DT et al (2018) Aqueous humor cytokine levels and anatomic response to intravitreal ranibizumab in diabetic macular edema. JAMA Ophthalmol 136(4):382–388
pubmed: 29522144
pmcid: 5876836
doi: 10.1001/jamaophthalmol.2018.0179
Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J et al (2019) Anatomic response to intravitreal dexamethasone implant and baseline aqueous humor cytokine levels in diabetic macular edema. Invest Ophthalmol Vis Sci 60:1336–1343
pubmed: 30933261
doi: 10.1167/iovs.18-26215
Figueras-Roca M, Sala-Puigdollers A, Alforja S et al (2019) Aqueous humour cytokine changes with intravitreal dexamethasone implant injection for diabetic macular edema. Ocul Immunol Inflamm 27(8):1203–1210
pubmed: 31418610
doi: 10.1080/09273948.2019.1636095
Rangasamy S, McGuire PG, Das A (2012) Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol 19(1):52–59
pubmed: 22346115
pmcid: 3277025
doi: 10.4103/0974-9233.92116
Doganay S, Evereklioglu C, Er H et al (2002) Comparison of serum NO, TNF-α , IL-1 , sIL- 2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16:163–170
pubmed: 11988817
doi: 10.1038/sj/eye/6700095
Gustavsson C, Agardh E, Bengtsson B et al (2008) TNF-α is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complicat 22:309–316
doi: 10.1016/j.jdiacomp.2007.03.001
Shimizu E, Funatsu H, Yamashita H et al (2002) Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. J Ophthalmol 46:78–83
Lee JH, Lee W, Kwon OH et al (2008) Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci 38(4):361–367
pubmed: 18988929
Wells JA, Glassman AR, Ayala AR et al (2015) Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203
pubmed: 25692915
doi: 10.1056/NEJMoa1414264
Massa H, Georgoudis P, Panos GD (2019) Dexamethasone intravitreal implant (OZURDEX®) for macular edema secondary to noninfectious uveitis: a review of the literature. Ther Deliv 10(6):343–351
pubmed: 31184554
doi: 10.4155/tde-2019-0024
Mackensen F, Heinz C, Becker MD et al (2008) Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28:41–45
pubmed: 18185136
doi: 10.1097/IAE.0b013e318156db75
Gonzalez VH, Campbell J, Holekamp NM et al (2016) Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 172:72–79
pubmed: 27644589
doi: 10.1016/j.ajo.2016.09.012
Goldhardt R, Rosen BS (2016) Uveitic macular edema: treatment update. Curr Ophthalmol Rep 4:30–37
pubmed: 27347446
pmcid: 4917282
doi: 10.1007/s40135-016-0090-3
Wilkinson CP, Ferris FLr, Klein RE, et al. (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110(9):1677–1682
pubmed: 13129861
doi: 10.1016/S0161-6420(03)00475-5
Wu L, Fernandez-Loaiza P, Sauma J et al (2013) Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes 4(6):290–294
pubmed: 24379919
pmcid: 3874488
doi: 10.4239/wjd.v4.i6.290
Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509–516
pubmed: 16196117
doi: 10.1016/j.ajo.2005.03.057
Jaffe GJ, Dick AD, Brézin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932–943
pubmed: 27602665
doi: 10.1056/NEJMoa1509852
Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 17(388):1183–1192
doi: 10.1016/S0140-6736(16)31339-3
Hillier RJ, Ojaimi E, Wong DT et al (2017) Aqueous humor cytokine levels as biomarkers of disease severity in diabetic macular edema. Retina 37(4):761–769
pubmed: 27471825
doi: 10.1097/IAE.0000000000001210
Mesquida M, Drawnel F, Lait PJ et al (2019) Modelling macular edema: the effect of IL-6 and IL-6R blockade on human blood-retinal barrier integrity in vitro. Transl Vis Sci Technol 28(8):32
doi: 10.1167/tvst.8.5.32
Figueras-Roca M, Molins B, Sala- Puigdollers A, et al. (2017) Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema. PLoS One 12(3):e0173865
pubmed: 28328965
pmcid: 5362077
doi: 10.1371/journal.pone.0173865
Ribeiro FP, Furlaneto CJ, Hatanaka E et al (2003) mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. Mediat Inflamm 12(3):173–178
doi: 10.1080/0962935031000134897
Myśliwiec J, Kretowski A, Topolska J et al (2001) Serum Th1 and Th2 profile cytokine level changes in patients with Graves’ ophthalmopathy treated with corticosteroids. Horm Metab Res 33(12):739–743
pubmed: 11753760
doi: 10.1055/s-2001-19135
Chakravarthy U, Harding SP, Rogers CA et al (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 119:1399–1411
pubmed: 22578446
doi: 10.1016/j.ophtha.2012.04.015
Zehetner C, Kirchmair R, Huber S et al (2013) Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 97:454–459
pubmed: 23385630
doi: 10.1136/bjophthalmol-2012-302451
Lejoyeux R, Diwo E, Vallet H et al (2018) Infliximab and adalimumab in uveitic macular edema. Ocul Immunol Inflamm 26(7):991–996
pubmed: 30096013
doi: 10.1080/09273948.2018.1498110
Steeples LR, Spry P, Lee RWJ et al (2018) Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy. Int Ophthalmol 38(3):1357–1362
pubmed: 28608031
doi: 10.1007/s10792-017-0592-5
Ghasemi H (2018) Roles of IL-6 in ocular inflammation: a review. Ocul Immunol Inflamm 26(1):37–50
pubmed: 28146368
doi: 10.1080/09273948.2016.1277247
Ghasemi H, Ghazanfari T, Yaraee R et al (2011) Roles of IL-8 in ocular inflammations: a review. Ocul Immunol Inflamm 19(6):401–412
pubmed: 22106907
doi: 10.3109/09273948.2011.618902